Cavion (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition

Founded 2003 Series A Total: $31.10M Biotechnology, Health Care +1

Cavion, a clinical-stage pharmaceutical company, focuses on developing treatments for cancer and neurological disorders by selectively inhibiting the T-type calcium channel (Cav3). Founded in 2003, it has made strides in pioneering therapies that engage Cav3 for solid tumor treatment. The company is currently undergoing Phase 1 safety and dose-finding clinical trials for brain cancer, with the goal of enhancing the effectiveness of combined chemotherapy, radiation, and targeted therapies for all solid tumors. Cavion's neurology program aims to introduce non-addictive, non-opioid T-type calcium channel antagonists for patients suffering from neuropathic pain and is also developing therapies for other neurological diseases like essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. The company's last investment was a $26.10M Series A investment at 06 January 2017, with participation from Novartis Venture Fund, Lilly Ventures, and Enso Ventures. Cavion's focus on pioneering ion channel inhibition for cancer and neurological diseases, along with its promising preclinical studies and ongoing clinical trials, positions it as a potential disruptor in the biotechnology, healthcare, and pharmaceutical industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	••••••	3		06 Jan 2017
Debt Financing	••••••	-		10 Nov 2015
Seed Round	••••••	1	•••• ••••	22 Dec 2005

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

06 Jan 2017

Debt Financing

••••••

10 Nov 2015

Seed Round

••••••

•••• ••••

22 Dec 2005

FAQ About Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition

Cavion was founded in 2003.

Cavion operates in the following industries: Biotechnology, Health Care, Pharmaceutical.

Cavion has completed 3 funding rounds, raising a total of $31.10M. The latest funding stage is Series A.

Top alternatives and competitors to Cavion include OmiCure, Tarveda Therapeutics, CARsgen Therapeutics, Genprex, Inc., Alaunos Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Cavion and OmiCure are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Cavion

General Information

Track Cavion

Discover More

About Cavion

Funding Rounds & Investors (3)

Cavion Alternatives & Competitors

FAQ About Cavion

Don't just browse. Track.